CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP · Real-Time Price · USD
53.39
+2.95 (5.85%)
At close: Oct 9, 2026, 4:00 PM EDT
53.69
+0.30 (0.56%)
After-hours: Oct 9, 2026, 7:57 PM EDT
CRISPR Therapeutics AG Employees
CRISPR Therapeutics AG had 393 employees as of December 31, 2024. The number of employees decreased by 14 or -3.44% compared to the previous year. That makes CRISPR Therapeutics AG the 21,905th largest employer in the world and 2,865th in the United States.
Employees
393
Change (1Y)
-14
Growth (1Y)
-3.44%
Revenue / Employee
$34,076
Profits / Employee
-$1,147,936
Market Cap
5.16B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 393 | -14 | -3.44% |
| Dec 31, 2023 | 407 | -51 | -11.14% |
| Dec 31, 2022 | 458 | -15 | -3.17% |
| Dec 31, 2021 | 473 | 63 | 15.37% |
| Dec 31, 2020 | 410 | 106 | 34.87% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| PTC Therapeutics | 991 |
| Travere Therapeutics | 497 |
| Mirum Pharmaceuticals | 433 |
| Scholar Rock Holding | 289 |
| Cogent Biosciences | 258 |
| CG Oncology | 142 |
| Definium Therapeutics | 106 |
| Erasca | 103 |
CRSP News
- 2 days ago - Crispr Therapeutics price target lowered to $81 from $82 at BofA - TheFly
- 3 days ago - CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2026 - GlobeNewsWire
- 8 days ago - CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026 - GlobeNewsWire
- 26 days ago - CRISPR Therapeutics AG Transcript: Morgan Stanley 24th Annual Global Healthcare Conference - Transcripts
- 4 weeks ago - CRISPR Therapeutics to Present at the Morgan Stanley 24th Annual Global Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Crispr Therapeutics durability data ‘encouraging,’ says Morgan Stanley - TheFly
- 6 weeks ago - CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026 - GlobeNewsWire
- 6 weeks ago - CRISPR Therapeutics AG Slides: Corporate presentation - Filings